[A21-111] Tirbanibulin (actinic keratosis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2021
Project no.:
A21-111
Commission:
Commission awarded on 31.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Field therapy of non-hyperkeratotic, non-hypertrophic actinic keratoses (Olsen grade I) in the face or on the scalp of adults
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.